Funding profile · Inflammation and rare disease therapeutics

GEn1E Lifesciences

Two Form D notices, three years apart, are the entire filed record of a company that has been in the clinic since 2021. They report $22.5 million of equity sold and no outside vehicle of any kind.

$22.5MEquity sold across the two Form D notices on record
$17.0MSold of $18.2M offered, 89 investors, filed Dec 2022
$5.5MSold of $11.9M offered, 44 investors, filed Dec 2025
$7MSeed capital the company says carried its lead drug to Phase 2

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Aug 2019 Y Combinator, Summer 2019 batch Not disclosed Y Combinator YC data
2019 Seed at launch A little more than $1M Angels, including CROs working with the company Independent
Jul 2020 Strategic investment Not disclosed Vituity Company release
May 2022 Expanded partnership Not disclosed Inflect Health, the Vituity innovation arm Company release
Dec 2022 Equity offering, Rule 506(b) $17,025,023 sold of $18,223,556 89 Form D
Oct 2023 BARDA DRIVe contract, ASPECT endotyping program Not disclosed HHS, ASPR, BARDA Company release
Oct 2025 Equity offering, Rule 506(b), still open at filing $5,520,803 sold of $11,887,377 44 Form D
Named backers Not a round. The company’s own investor list Not disclosed Clear Ventures, Khosla Ventures, Endurance28, Stanford StartX, Y Combinator, Vituity and Inflect Health, plus “amazing angels like Dr. Francois Nader, Thomas Ebeling, and others” Company-stated

What the filings show

GEn1E Lifesciences Inc. · Form D · filed Dec 29, 2025

First sale
Oct 21, 2025
Offered
$11,887,377 equity
Sold
$5,520,803 · $6,366,574 remaining
Investors
44 · average about $125,000
Exemption
Rule 506(b) · no non-accredited investors
Related persons
Ritu Lal (executive officer, director); Soujanya Bhumkar (executive officer, director); Noor Kamruddin (director); Alan Levy (director); Francois Nader (director)
Filing
SEC EDGAR, CIK 0001752886

GEn1E Lifesciences Inc. · Form D · filed Dec 21, 2022

First sale
Dec 6, 2022
Offered
$18,223,556 equity
Sold
$17,025,023 · $1,198,533 remaining
Investors
89 · average about $191,000
Exemption
Rule 506(b) · no non-accredited investors
Related persons
Ritu Lal (chief executive officer and secretary, director); Soujanya Bhumkar (director); Alan Levy (director); Noor Kamruddin (director)
Filing
SEC EDGAR, CIK 0001752886, Delaware, 2018

Reading the filings

  1. Two notices, one filer, no vehicles.A full text EDGAR search for Form D filings naming GEn1E returns the company’s own two notices and nothing else: no special purpose vehicle, no syndicate series, no fund filing. For a YC biotech with a long angel list that is unusual, and the filed record is the whole record.
  2. Eighty-nine checks at institutional size.The 2022 offering sold $17,025,023 to 89 investors, an average of about $191,000 each, none of them non-accredited. That is too many names for a venture-only round and too large an average for a pure angel list. The shape fits a lead or two plus a long tail, or notes converting into the same security.
  3. Neither offering total is a round number.$18,223,556 and $11,887,377. Companies that negotiate a round file for $20,000,000. Totals this precise are usually the arithmetic of existing instruments, which is what convertible notes or SAFEs look like when they convert.
  4. The 2025 notice was filed late.First sale October 21, 2025, filed December 29, 2025: 69 days. Form D is due within 15 days. The 2022 notice was filed on day 15 exactly, so the deadline is understood inside the company.
  5. The announced number and the filed number do not meet.An investor publication wrote in May 2024 that the company reached Phase 2 “In just two and a half years and with just $7 million in seed capital”. The Form D filed four months before that Phase 2 started reports $17,025,023 already sold. One figure is a spend, the other a raise, and no public document bridges them.
  6. The board grew by one, and the addition writes checks.The 2022 filing lists four related persons. The 2025 filing lists five, adding Francois Nader as a director. The company names Dr. Francois Nader among its angels and calls him chairman of the board. In the same interval Soujanya Bhumkar moves from director to executive officer and director.
  7. Eight years in, it is still called seed.Every company description from 2022 to 2026 calls the capital behind the pipeline seed funding. No priced Series A or B has been announced and no filing describes one. The $6,366,574 unsold in the October 2025 offering is the nearest thing to a live round.

Commercial signals

Signal Detail Source type
Clinical NCT05795465, Phase 2 in ARDS, 52 estimated, recruiting since Apr 4, 2023, primary completion estimated Oct 2026. The registered primary outcome is safety and tolerability. Public record
Regulatory Orphan drug and rare pediatric disease designations for GEn-1123 in Duchenne, Jun 9, 2026. A priority review voucher becomes possible only on approval. Fast Track for GEn-1124 is company-stated. Independent
Federal BARDA DRIVe contract for the ASPECT endotyping program, announced Oct 2023. Value not disclosed. Company-stated
Licensed assets Two exclusive, worldwide, all fields University of Maryland, Baltimore licenses: p38 alpha in Dec 2019, ERK1/2 in Jul 2022. Royalty and milestone terms are not public. Independent
Revenue No approved product and no disclosed partnership or milestone revenue. Not found
Other non-dilutive No NIH or NSF awards appear in the federal grant records pulled here. Not found

What to watch

  • A closing or amended Form D for the October 2025 offering. $6,366,574 of it was unsold at the filing date.
  • A Form D from any vehicle named for the company. None exists today, so a new one would mark a change in how the round is assembled.
  • A priced round with a name, ending eight years of seed language.
  • Whether Phase 2 primary completion, estimated for October 2026, lands before or after the next raise.
  • A registered trial for GEn-1123. Designations do not become a voucher without one.

The GEn1E Lifesciences story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Ochre Bio: Shared investor: Company Partners. An Oxford company that designs RNA drugs and tests them in whole human donor livers kept alive on machines
  • Inito: Shared investor: M Angels. A smartphone connected urine test that reports four reproductive hormones as numbers instead of lines
  • Eugit Therapeutics: Also in Therapeutics. A San Francisco Bay Area biotech building a T cell receptor based delivery platform meant to steer drugs to diseased tissue
  • Perception Biosystems: Also in Therapeutics. A Y Combinator company that set out to build a robotic lab so a rare disease gene therapy could be made faster and far more cheaply

Sources

  1. Public recordForm D, GEn1E Lifesciences Inc., CIK 0001752886SEC · Dec 21, 2022
  2. Public recordForm D, GEn1E Lifesciences Inc., CIK 0001752886SEC · Dec 29, 2025
  3. Public recordEDGAR full text search for Form D filings naming GEn1E LifesciencesSEC · Sep 22, 2026
  4. Public recordClinicalTrials.gov NCT05795465, Phase 2 of GEn-1124 in ARDSAccessed Sep 22, 2026
  5. IndependentMeet GEn1E, the biotech bringing p38alpha kinase drugs to inflammatory diseasesFierce Biotech, Amirah Al Idrus · Jul 31, 2019
  6. IndependentGEn-1123 wins orphan drug, rare pediatric disease status for DMDMuscular Dystrophy News · Jun 11, 2026
  7. CompanyRiding the Fast Track to Pharma Success, an investor profile of GEn1EEndurance28, Tim Stobierski · May 2024
  8. CompanyPartnership with BARDA on the ASPECT endotyping programPR Newswire · Oct 24, 2023
  9. CompanyVituity and Inflect Health partnership announcementsBusiness Wire Jul 30, 2020 and PR Newswire May 12, 2022
  10. CompanyUS FDA grants orphan drug and rare pediatric disease designations for GEn-1123Business Wire · Jun 9, 2026
  11. CompanyGEn1E Lifesciences about page, team, board and investor listAccessed Sep 22, 2026

Compiled from SEC, ClinicalTrials.gov and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in GEn1E Lifesciences. This page is not an offer to sell or a recommendation to buy any security.